Deutsche Bank AG vs BIO-TECHNE Corp — how do they compare? Deutsche Bank AG trades at $35.68 (market cap $67.54B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Deutsche Bank AG is far larger — about 6.1× BIO-TECHNE Corp's market cap, and Deutsche Bank AG pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| DB | TECH | |
|---|---|---|
Market Cap | $67.54B | $11.12B |
Sector | Financials | Health |
52-Week High | $40.33 | $71.38 |
52-Week Low | $28.37 | $43.31 |
Dividend Yield | 3.3% | 0.45% |
Enterprise Value | — | $11.20B |
Trailing returns across standard periods
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →